Previous 10 | Next 10 |
home / stock / ucbjy / ucbjy news
New Three-Year Bimekizumab Data Reinforce Long-Term Maintenance of Complete Skin Clearance in Moderate to Severe Plaque Psoriasis PR Newswire Three-year data from the BE BRIGHT open-label extension study are being presented at the 31st EADV Congress Over eight out ...
UCB Showcases Strength of the Expanding Dermatology Portfolio at the 31st EADV Congress PR Newswire 20 abstracts highlight research in key disease areas including psoriasis and psoriatic arthritis New three-year data to be presented on bimekizumab in the treatment ...
The U.S. Food and Drug Administration granted orphan drug designation to UCB's (OTCPK:UCBJY) (OTCPK:UCBJF) fenfluramine hydrochloride to treat seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder. CDKL5 deficiency disorder is a rare developmental epileptic ...
First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022 PR Newswire New data from BE MOBILE 1 and BE MOBILE 2 show that bimekizumab achieved consistent improvements versus placebo in signs and s...
UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022 PR Newswire First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriat...
Amid the biotech bear market, there are companies that are trading on a deep bargain, yet you should be extremely careful before averaging down. Though I noticed the fundamental changes in Galapagos, I gave the company a year to turn around. Here, I presented to you three differen...
UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis PR Newswire Phase 3 RAISE and MycarinG studies in generalized myasthenia gravis (gMG) show zilucoplan and rozanolixizumab improve gMG-specific outcomes with con...
JAMA Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of FINTEPLA® (fenfluramine) Oral Solution in Lennox-Gastaut Syndrome (LGS) PR Newswire Primary endpoint was met demonstrating that FINTEPLA, as adjunctive treatment, is effective in signific...
UCB Showcases Strength of Broad Neurology Portfolio at 74th American Academy of Neurology (AAN) Annual Meeting PR Newswire Scientific presentations illustrate UCB's commitment to addressing unmet needs of people living with a broad range of serious neurological disease...
FINTEPLA® (fenfluramine) Oral Solution Now FDA Approved for Treatment of Seizures Associated with Lennox-Gastaut Syndrome (LGS) PR Newswire FINTEPLA ® has demonstrated efficacy in the most difficult-to-treat seizure types, 1 ,2 including drop se...
News, Short Squeeze, Breakout and More Instantly...
UCB S.A. ADR Company Name:
UCBJY Stock Symbol:
OTCMKTS Market:
FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia PR Newswire FINTEPLA is approved by the U.S. Food and Drug Administration (FDA) for the treatment of ...
New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels PR Newswire Pharmacokinetic data from the CHERISH study suggest that pregnant women treated with certolizumab pegol can ...
UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 PR Newswire Patients with non-radiographic axial spondyloarthritis (nr-axSpA) and those with ankylosing spondylitis (AS) treated ...